Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Zenas BioPharma will present updates on orelabrutinib and obexelimab at MSToronto2026, including Phase 3 trial designs for orelabrutinib in non-active secondary progressive multiple sclerosis and primary progressive multiple sclerosis. New results from a Phase 2 relapsing-remitting multiple sclerosis study of orelabrut
Zenas BioPharma announced that it will present seven posters at MSToronto2026, including data on Orelabrutinib for relapsing remitting multiple sclerosis, clinical trial designs for progressive multiple sclerosis, and other data from its multiple sclerosis portfolio.
Zenas BioPharma said it will present orelabrutinib data in relapsing remitting multiple sclerosis, trial designs in progressive multiple sclerosis and other portfolio data at MSToronto2026.